Showing posts with label Siemens Healthcare GmbH. Show all posts
Showing posts with label Siemens Healthcare GmbH. Show all posts

Wednesday 2 January 2019

Heart Attack Diagnostics Market Expected To Trigger A Revenue Increase To USD 15.4 Billion By 2024:Key Participant Siemens Healthcare GmbH, Schiller AG


San Francisco, 03 January ,  Heart Attack Diagnostics Market Analysis by Test type (Electrocardiogram, Blood Tests (Troponin, CK-MB), Echocardiogram), by Region (U.S., Canada, UK, Germany, China, India, Brazil, Mexico, South Africa, Middle East), and Segment Forecasts to 2024.


The heart attack diagnostics market is expected to reach USD 15.4 billion by 2024, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to witness a lucrative growth during the forecast period from2016 to 2024. From 2001 to 2011, age-standardized, heart attack incidence rates have significantly decreased worldwide. However, the overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth. 
The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.  

Access Full Research Report On Heart Attack Diagnostics  Analysis:

Further key findings from the study suggest:
·         North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.
·         The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.
·         The troponin blood test type is the largest grossing segment and is expected to capture the largest share in 2015, especially in developing countries including Brazil, China, and India. Its applications as a cardiac monitoring device and its indispensable use as a heart attack diagnostic tool will be a contributing factor supporting the market growth. The industry comprises of several local as well as global players. Some of the major players of this industry include Siemens Healthcare GmbH, Schiller AG, GE Healthcare, and Hitachi Medical Systems. 
Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the heart attack diagnostics market on the basis of product and region: 
Heart Attack Diagnostics Test Type Outlook (Revenue, USD Million, 2013 - 2024)
·         Electrocardiogram (ECG)
·         Blood tests
o    Troponin
o    CK-MB
o    Others
·         Others
Heart Attack Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o    UK
·         Asia Pacific
o    China
o    India
·         Latin America
o    Brazil
o    Mexico
·         MEA
o    Middle East
o    South Africa


Access Full Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/


Wednesday 24 October 2018

Therapeutic Drug Monitoring Market Expected To Trigger A Revenue Increase To USD 3.37 Billion By 2024:Key Participant Siemens Healthcare GmbH


San Francisco, 24 October 2018 , The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.
The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.
Full Research Report On Therapeutic Drug Monitoring Market Analysis:
www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market

Further key findings from the study suggest:
·         The consumables segment covered over 65% of the market share in 2015 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.
·         The immunoassay segment held the largest market share in 2015. The presence of several commercially available immunoassays combined with their associated benefits including the cost effectiveness and easy-to-handle nature of the products are the key drivers for the growth of this segment.
·         The proteomics category is expected to be the fastest growing technology segment due to the advent of various proteomic technologies, such as isotope-coded affinity tags, next generation sequencing, and protein microarray platforms that enable rapid mining of the proteome.
·         The hospital is the largest end-use segment with a share of over 60% in 2015. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.
·         The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.
·         In 2015, North America was the highest revenue generating region with revenue generated over USD 900 million. The rising number of R&D activities coupled with the high awareness about personalized therapy is the major determining factor for the large share captured by the North America region.
·         Few of the leading market players are Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMérieux, Inc., and Alere, Inc. The persistent R&D efforts are being undertaken along with numerous other strategic endeavors being adopted by the market players with the objective of enhancing the present drug monitoring practices and to develop novel technologies.
Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the therapeutic drug monitoring market on the basis of product, technology, application, end-use, and region:
Therapeutic Drug Monitoring Market, Product Outlook, by Revenue (USD Million, 2013 - 2024)
·         Consumables
·         Equipment
·         Others
Therapeutic Drug Monitoring Market, Technology Outlook, by Revenue (USD Million, 2013 - 2024)
·         Immunoassays
·         Proteomic technologies
·         Others
Therapeutic Drug Monitoring Market Drug, Class Outlook, by Revenue (USD Million, 2013 - 2024)
·         Anti-epileptics
·         Antibiotics
·         Immunosuppressants
·         Psychoactive drugs
·         Antiarrhythmic drugs
·         Others
Therapeutic Drug Monitoring Market, End-use Outlook, by Revenue (USD Million, 2013 - 2024)
·         Hospital labs
·         Private labs
·         Others
Therapeutic Drug Monitoring Market, Regional Outlook, by Revenue (USD Million, 2013 - 2024)
·         North America
o    U.S.
o    Canada
·         Europe
o    UK
o    Germany
·         Asia Pacific
o    Japan
o    China
·         Latin America
o    Brazil
·         MEA
o    South Africa


About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/


Wednesday 10 October 2018

Cardiac Biomarkers Market Expected To Trigger A Revenue Increase To USD 13.3 Billion By 2024:Key Participant Alere, Inc., Siemens Healthcare GmbH

San Francisco, 10 October 2018, The Cardiac Biomarkers Market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast period from 2016 to 2024.
Analysis of global market trends focuses on the increasing demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (ACS), continual technological advancements in the development of cardiovascular biomarkers, increasing number of new product launches by the key market players, rising demand for point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute myocardial infarction.
The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI, respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. ACS is expected to be the highest grossing segment according to the study. ACS is responsible for huge medical costs globally and is responsible for most hospital readmission cases. The increasing efforts to cut down worldwide ACS prevalence rates are expected to drive the growth of the biomarkers market.
The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is anticipated to be the fastest growing region during the forecast period.
Full Research Report On cardiac biomarkers market Analysis:www.grandviewresearch.com/industry-analysis/cardiac-biomarker-market

 Further key findings from the study suggest:
  • North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of coronary heart disease in western countries is one of the major factors contributing to the high demand for cardiac biomarker diagnostics.
  • The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker diagnostics.
  • The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the highest CAGR compared to others and accounts for the largest market share in 2015.
  • The sector comprises of several local as well as global players. Some of the major players of this vertical include Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.
Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the cardiac biomarkers market on the basis of type, application, end use, and region:
Cardiac Biomarkers Type Outlook (Revenue, USD Million, 2013 - 2024)
  • Troponin
  • CK-MB
  • Natriuretic peptides - BNP and NT-proBNP
  • Myoglobin
  • Others
Cardiac Biomarkers Market Application Outlook (Revenue, USD Million, 2013 - 2024)
  • Acute Coronary Syndrome
  • Myocardial infarction
  • Congestive heart failure
  • Others
Cardiac Biomarkers Market End-use Outlook (Revenue, USD Million, 2013 - 2024)
  • Laboratory Testing
  • Point of Care Testing
Cardiac Biomarkers Regional Outlook (Revenue, USD Million, 2013 - 2024)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa
    • Middle East
  Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-cardiac-biomarker-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/